InebilizumabMeSH Supplementary Concept

https://ansm.sante.fr/tableau-marr/inebilizumab
2024
false
false
false
France
French
risk management
inebilizumab
inebilizumab
infusions, intravenous
patients guideline
product surveillance, postmarketing
patient safety
adult
neuromyelitis optica
Immunosuppression-related infectious disease (disorder)
leukoencephalopathy, progressive multifocal
virus diseases
serious infection

---
https://www.has-sante.fr/jcms/p_3444098/fr/uplizna-inebilizumab-neuromyelite-optique
2023
false
false
false
France
neuromyelitis optica spectrum disorders who are anti-aquaporin 4 antibody positive
treatment outcome
insurance, health, reimbursement
inebilizumab
adult
Neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
Anti-aquaporin 4 antibody positivity
evaluation of the transparency committee
inebilizumab
neuromyelitis optica

---
https://www.has-sante.fr/jcms/p_3390335/fr/uplizna-inebilizumab-neuromyelite-optique
2022
false
false
false
France
inebilizumab
treatment outcome
adult
infusions, intravenous
neuromyelitis optica spectrum disorders who are anti-aquaporin 4 antibody positive
Neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
Anti-aquaporin 4 antibody positivity
evaluation of the transparency committee
neuromyelitis optica
inebilizumab

---
https://www.has-sante.fr/jcms/p_3341895/fr/uplizna-inebilizumab-maladies-du-spectre-de-la-neuromyelite-optique-nmosd
https://has-sante.fr/jcms/p_3341911/fr/decision-n-2022-0299/dp/sem-du-25-mai-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-uplizna
2022
false
false
false
France
inebilizumab
insurance, health, reimbursement
treatment outcome
adult
Anti-aquaporin 4 antibody positivity
infusions, intravenous
rare diseases
critical illness
evaluation of the transparency committee
inebilizumab
neuromyelitis optica

---
https://www.ema.europa.eu/en/medicines/human/EPAR/uplizna
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
inebilizumab
inebilizumab
Anti-aquaporin 4 antibody positivity
neuromyelitis optica
neuromyelitis optica
infusions, intravenous
inebilizumab
neuromyelitis optica spectrum disorders who are anti-aquaporin 4 antibody positive
anti-aquaporin 4 autoantibody
drug interactions
pregnancy
breast feeding
drug approval
europe
drug evaluation, preclinical
adult

---